Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
Crossref DOI link: https://doi.org/10.1186/s13045-016-0280-3
Published Online: 2016-06-28
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lehmann, Christian
Friess, Thomas
Birzele, Fabian
Kiialainen, Anna
Dangl, Markus